Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford Immunotec and Lophius Biosciences have signed licensing and collaboration agreements for the development and commercialization of novel T-cell based assays.
Subscribe to our email newsletter
Under the deals, Oxford will have access to Lophius’ UREA technology while Lophius will gain access to Oxford’s T-SPOT technology.
Oxford chief executive officer Dr. Peter Wrighton-Smith said, "We believe that Lophius’s UREA technology has distinct advantages over conventional methods of designing and producing antigens for T-cell based diagnostic test systems."
Financial details of the deals have not been revealed.
Lophius managing director Dr. Michael Lutz said, "This cooperation also confirms the commercial potential of our proprietary UREA technology platform which led to recent successful development of two CE-marked tests, namely T-Track CMV and T-Track EBV."